AAAAAA

   
Results: 1-15 |
Results: 15
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging
Authors: Kline, RP Wu, EX Petrylak, DP Szabolcs, M Alderson, PO Weisfeldt, ML Cannon, P Katz, J
Citation: Rp. Kline et al., Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging, CLIN CANC R, 6(6), 2000, pp. 2146-2156
Management of advanced/metastatic prostate cancer: 2000 update - The Hussain/Dawson article reviewed
Authors: Petrylak, DP
Citation: Dp. Petrylak, Management of advanced/metastatic prostate cancer: 2000 update - The Hussain/Dawson article reviewed, ONCOLOGY-NY, 14(12), 2000, pp. 1694-1694
Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A southwest oncology group study
Authors: Hussain, M Fisher, EI Petrylak, DP O'Connor, J Wood, DP Small, EJ Eisenberger, MA Crawford, ED
Citation: M. Hussain et al., Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A southwest oncology group study, J CL ONCOL, 18(5), 2000, pp. 1043-1049
Southwest oncology group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trialend point
Authors: Small, EJ Lew, D Redman, BG Petrylak, DP Hammond, N Gross, HM Eastham, JA Crawford, ED
Citation: Ej. Small et al., Southwest oncology group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: The importance of survival as a clinical trialend point, J CL ONCOL, 18(13), 2000, pp. 2537-2544
Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients
Authors: Lee, N Fawaaz, R Olsson, CA Benson, MC Petrylak, DP Schiff, PB Bagiella, E Singh, A Ennis, RD
Citation: N. Lee et al., Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients, INT J RAD O, 48(5), 2000, pp. 1443-1446
Docetaxel (Taxotere) in hormone-refractory prostate cancer
Authors: Petrylak, DP
Citation: Dp. Petrylak, Docetaxel (Taxotere) in hormone-refractory prostate cancer, SEMIN ONCOL, 27(2), 2000, pp. 24-29
The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer
Authors: Ennis, RD Petrylak, DP Singh, P Bagiella, E O'Toole, KM Benson, MC Olsson, CA
Citation: Rd. Ennis et al., The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer, J UROL, 163(5), 2000, pp. 1413-1418
Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer
Authors: Weitzman, AL Shelton, G Zuech, N Owen, CE Judge, T Benson, M Sawczuk, I Katz, A Olsson, CA Bagiella, E Pfaff, C Newhouse, JH Petrylak, DP
Citation: Al. Weitzman et al., Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer, J UROL, 163(3), 2000, pp. 834-837
Chemotherapy for metastatic renal cell carcinoma (RCC)
Authors: Ruiz, JA Raftopoulos, H Petrylak, DP
Citation: Ja. Ruiz et al., Chemotherapy for metastatic renal cell carcinoma (RCC), CUR CLIN ON, 4, 2000, pp. 283-300
Refractory disease, new horizons and patient-physician relationships
Authors: Glode, LM Petrylak, DP
Citation: Lm. Glode et Dp. Petrylak, Refractory disease, new horizons and patient-physician relationships, PROSTATE C, 2, 1999, pp. 19-20
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
Authors: Petrylak, DP Macarthur, RB O'Connor, J Shelton, G Judge, T Balog, J Pfaff, C Bagiella, E Heitjan, D Fine, R Zuech, N Sawczuk, I Benson, M Olsson, CA
Citation: Dp. Petrylak et al., Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer, J CL ONCOL, 17(3), 1999, pp. 958-967
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
Authors: Bubley, GJ Carducci, M Dahut, W Dawson, N Daliani, D Eisenberger, M Figg, WD Freidlin, B Halabi, S Hudes, G Hussain, M Kaplan, R Myers, C Oh, W Petrylak, DP Reed, E Roth, B Sartor, O Scher, H Simons, J Sinibaldi, V Small, EJ Smith, MR Trump, DL Vollmer, R Wilding, G
Citation: Gj. Bubley et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group, J CL ONCOL, 17(11), 1999, pp. 3461-3467
Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer
Authors: Petrylak, DP Macarthur, R O'Connor, J Shelton, G Weitzman, A Judge, T England-Owen, C Zuech, N Pfaff, C Newhouse, J Bagiella, E Hetjan, D Sawczuk, I Benson, M Olsson, C
Citation: Dp. Petrylak et al., Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer, SEMIN ONCOL, 26(5), 1999, pp. 28-33
Chemotherapy for advanced hormone refractory prostate cancer
Authors: Petrylak, DP
Citation: Dp. Petrylak, Chemotherapy for advanced hormone refractory prostate cancer, UROLOGY, 54(6A), 1999, pp. 30-35
Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients
Authors: Lee, N Newhouse, JH Olsson, CA Benson, MC Petrylak, DP Schiff, PB Bagiella, E Malyszko, B Ennis, RD
Citation: N. Lee et al., Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients, UROLOGY, 54(3), 1999, pp. 490-494
Risultati: 1-15 |